These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

72 related articles for article (PubMed ID: 3705967)

  • 1. [In vitro biopharmaceutical control of pharmaceutical preparations. 8. Mathematical method for the evaluation of dissolution curves determined in flow-through cells].
    Kissné CE; Keserü P
    Acta Pharm Hung; 1986 Mar; 56(2):65-71. PubMed ID: 3705967
    [No Abstract]   [Full Text] [Related]  

  • 2. [The importance of micronization in the design of dosage forms I. Theoretical and biopharmaceutical aspects].
    Antal I
    Acta Pharm Hung; 2006; 76(2):95-103. PubMed ID: 17094668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [In vitro biopharmaceutical control of pharmaceutical preparations. 7. Design and experimental study of flow through cells applicable to dissolution tests].
    Kissné Csikós E; Keserü P
    Acta Pharm Hung; 1986 Jan; 56(1):26-33. PubMed ID: 3953284
    [No Abstract]   [Full Text] [Related]  

  • 4. Regulatory aspects of modified release dosage forms: special cases of dissolution testing using the flow-through system.
    Möller H; Wirbitzki E
    Boll Chim Farm; 1993 Apr; 132(4):105-15. PubMed ID: 8333916
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Current perspectives in dissolution testing of conventional and novel dosage forms.
    Azarmi S; Roa W; Löbenberg R
    Int J Pharm; 2007 Jan; 328(1):12-21. PubMed ID: 17084051
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Investigations in Bioavailability of resinates as peroral retard drug dosage forms. Part 1: Pharmaceutical availability of dihydrocodein-resinates (author's transl)].
    Mühlenbruch B; Strauss H; Glaubitz H
    Pharmazie; 1982 Mar; 37(3):200-3. PubMed ID: 7100242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Use of the dissolution test in controlling the bioavailability of solid oral pharmaceutical forms].
    Carli F; Ceriani D; Frattini C; Gorlato P; Maffione G; Moro L; Neri G; Ciranni Signoretti E
    Ann Ist Super Sanita; 1982; 18(3):551-8. PubMed ID: 7187844
    [No Abstract]   [Full Text] [Related]  

  • 8. [Bioequivalence in vitro evaluation of some antibacterial generic dosage forms].
    Semdé R; Ouédraogo HW; Guissou IP; Amighi K
    J Pharm Belg; 2005; 60(2):51-5. PubMed ID: 16035369
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [In-vitro dissolution tests. Influence of the execution conditions].
    Simioni L; Bottoni R
    Boll Chim Farm; 1973 Mar; 112(3):191-200. PubMed ID: 4721643
    [No Abstract]   [Full Text] [Related]  

  • 10. [Utilization of analog computers in the development of dosage forms].
    Frömming KH; Lippold B; Garrett ER
    Mitt Dtsch Pharm Ges Pharm Ges DDR; 1971 Sep; 41(9):205-47. PubMed ID: 4939073
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro biopharmaceutical investigation of antacid activity in standard dissolution test apparatus.
    Plachy J; Antal I; Rácz I; Kulcsár-Molnár Z; Muskáth Z
    Acta Pharm Hung; 1995 Jan; 65(1):23-6. PubMed ID: 7725926
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell.
    Motz SA; Schaefer UF; Balbach S; Eichinger T; Lehr CM
    Eur J Pharm Biopharm; 2007 May; 66(2):286-95. PubMed ID: 17156983
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dissolution test development for complex veterinary dosage forms: oral boluses.
    Fahmy R; Marnane B; Bensley D; Hollenbeck RG
    AAPS PharmSci; 2002; 4(4):E35. PubMed ID: 12646007
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Partitioning phenomena in dosage form and biopharmaceutical design. 3. Some partitioning considerations in drug absorption, distribution, response and elimination.
    Schumacher GE
    Am J Hosp Pharm; 1972 Apr; 29(4):339-43. PubMed ID: 5025265
    [No Abstract]   [Full Text] [Related]  

  • 15. Probability of passing dissolution acceptance criteria for an immediate release tablet.
    Dumont ML; Berry MR; Nickerson B
    J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Role of mass transfer processes in drug formulation].
    Rácz I; Marton S; Antal I; Plachy J; Csóka G
    Acta Pharm Hung; 1996 May; 66(3):105-10. PubMed ID: 8975536
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Biopharmaceutical considerations of dissolution testing used as a prognostic tool for oral drug adsorption].
    Antal I
    Acta Pharm Hung; 2001 Oct; 71(3):280-8. PubMed ID: 11961894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Salt formation to improve drug solubility.
    Serajuddin AT
    Adv Drug Deliv Rev; 2007 Jul; 59(7):603-16. PubMed ID: 17619064
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A new approach to modelling the relationship between in vitro and in vivo drug dissolution/absorption.
    Dunne A; O'Hara T; Devane J
    Stat Med; 1999 Jul; 18(14):1865-76; discussion 1877. PubMed ID: 10407257
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prediction of human pharmacokinetics--gastrointestinal absorption.
    Fagerholm U
    J Pharm Pharmacol; 2007 Jul; 59(7):905-16. PubMed ID: 17637184
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.